GlassScriptPhysician profile
Kathryn Robertson
NPI 1386900983
$7,568.84
in general payments reported to CMS, 2019-2025
35 companies · $2,262 in 2025
The $2,262 reported for 2025 was more than what 96% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $895 · 2022: $1,077 · 2023: $1,645 · 2024: $1,691 · 2025: $2,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,597.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,343.67 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,090.82 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $621.13 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $544.56 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $386.85 | 2021-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $283.77 | 2023-2025 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $277.05 | 2021-2023 | Injectafer |
| Celgene Corporation | $230.97 | 2023-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $222.16 | 2024-2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $221.06 | 2021-2023 | |
| Ardelyx, INC. | $160.05 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $124.49 | 2024 | |
| Celltrion USA INC. | $119.67 | 2025 | Vegzelma |
| Pfizer INC. | $98.06 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $85.61 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $83.30 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $79.17 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $78.47 | 2021-2024 | Sutab |
| Novo Nordisk INC | $67.60 | 2023-2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $60.56 | 2023-2025 | Ocaliva |
| Lilly USA, LLC | $49.96 | 2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $47.52 | 2023-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $34.08 | 2022-2023 | Dupixent |
| Amgen INC. | $33.78 | 2023 | Amjevita |
| Gilead Sciences, INC. | $31.17 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $30.24 | 2021-2022 | |
| Enterra Medical, INC. | $24.69 | 2023 | |
| Organon LLC | $20.64 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $20.21 | 2023 | Dificid |
| Mirum Pharmaceuticals, INC. | $19.15 | 2025 | Livmarli |
| Sandoz INC. | $18.19 | 2025 | Hyrimoz |
| Redhill Biopharma INC. | $17.15 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.35 | 2023 | Cyltezo |
| Mallinckrodt Hospital Products INC. | $15.03 | 2023 | Terlivaz |
| Endogastric Solutions, INC | $12.66 | 2024 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Robertson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.